Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
7,271 total articles
Park Aerospace supplies advanced composite and hot-melt materials used across aerospace and defense. With recent 20% sales growth and doubled EPS, no debt, and a multicast of defense spending tailwinds, PKE looks like a tactical long. Valuation is rich, and a $150M share-and-warrant deal introduces dilution risk — this trade pairs momentum with dis…
Douglas Dynamics has gone from recovery to record results in 2025 and is trading well above its 52-week low. Fundamentals and seasonality favor more upside; technicals and a compact float keep this a tradable long. Here’s a concrete entry, stop and target with rationale and risks.
Clarivate is cheap on multiple cash-based metrics. Recent Q4 beats, guidance for double-digit free cash flow growth, and talks to divest Life Sciences position it to materially cut leverage. If execution holds, the stock can re-rate from cyclical distressed multiples to a more normal software/analytics multiple. This trade targets a move to $6 on a…
Snowflake is down sharply in 2026 despite 30% revenue growth, improving AI positioning, and strong free cash flow. The pullback has created a tradable entry at $182.81 with asymmetric upside to $260 while limiting risk with a $150 stop. This is a long-term trade (180 trading days) sized to account for headline risk and execution uncertainty.
Riley Exploration (RILEY) is a small Permian-focused E&P that can deliver outsized returns if oil stays above $75/bbl. Public financial disclosure on the name is limited and liquidity can be thin, but the company's cost structure and drilling optionality give it attractive upside in a tightening crude market. This is a high-risk, high-reward trade …
Zeta Global (ZETA) has re-emerged as a growth story after a series of strong top-line prints and expanding free cash flow. The market has mostly reset expectations from its 2025 slump, yet valuation still implies meaningful future growth. This trade idea outlines a mid-term long with an entry near the current price, a stop below recent intraday low…
Copart (CPRT) checks the boxes for a tactical long: solid free cash flow ($1.41B), effectively no debt, and a share base that management can meaningfully pare without risking leverage. We recommend buying near $37.56 to play an expected repurchase cycle and earnings re-acceleration over the next 180 trading days.
The Trade Desk (TTD) has been pummeled from its highs but still runs a profitable, high-retention ad-tech engine. CEO Jeff Green's recent $148M buy is a meaningful signal. This trade idea lays out a mid-term long with a clearly defined entry, stop and target, anchored to fundamentals (record 2025 revenue, strong FCF) and near-term catalysts (OpenAI…
Navan's share price sits near the low of its first year public, trading at roughly $10 with a $2.46B market cap. Technicals show short-term stabilization and bullish MACD momentum, while headlines about rising sales & marketing spend and pending securities suits keep sentiment weak. This trade idea outlines a mid-term (45 trading days) long with an…
HIMS gapped higher after settling with Novo Nordisk and striking a distribution deal for Wegovy/Ozempic; the move removes a headline risk and creates a tactical mid-term buying opportunity. Valuation is reasonable relative to growth expectations but volatility, execution risk on international expansion, and GLP-1 market dynamics argue for a discipl…
Vicor (VICR) is a niche leader in high-density power modules that has become a direct beneficiary of AI and data-center buildouts. Strong Q3 results, favorable ITC rulings, and an accelerating licensing stream support a bullish case. The shares are expensive on traditional metrics but justify a premium if Vicor hits scale targets; this trade outlin…
Micron is positioned to capture the AI memory squeeze thanks to HBM demand, an oligopolistic supply base and a massive capex program. The stock is expensive by traditional multiples but the growth and cash generation story justifies a targeted long with a disciplined stop. Entry, stop and target included for a 180-trading-day campaign.
Vermilion Energy (VET) owns meaningful upstream gas exposure in France, Netherlands, Germany and Ireland and is starting 2026 with lower debt, a raised quarterly dividend and bullish technicals. With market cap of $1.75B, a dividend yield north of 3%, and sizable short interest, VET offers an asymmetric trade if European gas prices spike. This idea…
Hims & Hers (HIMS) surged after resolving its dispute with Novo Nordisk and securing distribution of GLP-1 products on its platform. The deal removes a major overhang, pairs with a $1.15B Eucalyptus acquisition to accelerate international growth, and leaves the stock trading at a reasonable multiple for a recovery trade. This is a mid-term swing tr…
AngloGold Ashanti (AU) looks like a high-conviction buy on a pullback. The shares are trading near the 50-day EMA and well below the 52-week high, while the company continues to demonstrate asset monetization, strategic investments, and a cash-generative portfolio. This trade targets a return to the upper-$120s over the next 180 trading days with a…
Euroseas is trading at bargain multiples (P/E 3.3, P/B ~1.0) with a market cap of ~$460M and an upcoming ex-dividend date on 03/10/2026. Recent time charters for fuel-efficient 1,800 TEU feeders at $22k-$24.25k/day and a technically constructive setup support a mid-term long trade. The trade carries cyclical and execution risks; use a clear stop an…
Snowflake (SNOW) has pulled back from its 52-week highs but still trades at premium multiples. With a $61.6B market cap, 30% reported revenue growth, and clear AI positioning, the stock offers a tactical long opportunity for investors willing to accept valuation and legal risk. This trade idea lays out entry, stop, targets, catalysts, and the scena…
Nvidia remains dominant in AI hardware, but the stock's multiple and recent technical drift suggest the market is pricing perfection. With P/E in the mid-30s, price-to-sales above 20, and bearish momentum indicators, this trade idea sells a controlled short at current levels with a $145 target and a $195 stop over a mid-term (45 trading days) horiz…
Uranium Royalty Corp. (UROY) offers investors a way to participate in higher uranium prices through a growing royalty portfolio and selective physical holdings. At a market cap of roughly $504.6M and a share price near $3.65, UROY is a leveraged, lower-capex play on the sector. This note lays out a mid-term (45 trading days) swing trade: entry $3.6…
Elbit Systems (ESLT) is the primary Israeli drone and defense-systems supplier benefiting directly from the recent Iran strikes and elevated regional tensions. With a $25.2 billion backlog, fresh contract wins totaling roughly $663 million announced in recent months, and bullish technical momentum, we upgrade ESLT to a buy for a long-term trade. El…
CVR Partners (UAN) is trading below its 52-week high after a distribution payment and a volatile open, leaving a $119.54 stock that yields ~9.4% and trades at an EV/EBITDA of about 8.7. Recent supply-risk chatter out of the Middle East has pushed ammonia/UAN price expectations higher; combine that with CVR's cash-generation (free cash flow ~$98.8M)…
Arista is capturing outsized demand from AI data-center upgrades. Recent quarter beat, raised guidance, a $5.4B deferred backlog, and strong free cash flow argue for a long exposure. Valuation is rich but not irrational given growth; position size and a strict stop are essential.
Peoples Financial Services (PFIS) looks oversold on momentum but fundamentally intact: low-teens return on equity, manageable debt, steady dividend growth and a P/B around 1.0 argue against an immediate downgrade. This trade targets a rebound to prior highs while protecting downside with a pragmatic stop.
Immatics is trading near a financing-induced floor after a December 2025 $10 underwritten offering and is showing multiple positive clinical readouts across its TCR-T and TCER pipelines. This trade idea treats today's price as a de-risked entry into a high-upside clinical-stage oncology story: conservative near-term upside to low double-digits and …
Positive cardiopulmonary results from the DELIVER trial and the initiation of the Phase 3 HARMONIA study for z-basivarsen (DYNE-101) meaningfully de-risk Dyne's clinical story. With shares trading near $17 and market cap around $2.8B, the setup favors a disciplined long swing trade that captures further validation and potential re-rating as late-st…
